Materiały źródłowe

• #1 Brugada syndrome – Diagnosis & treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/brugada-syndrome/diagnosis-treatment/drc-20370494

  Treatment for Brugada syndrome may include medication, catheter procedures or surgery to implant a device that controls the heartbeat. Brugada syndrome treatment depends on the risk of having a serious irregular heartbeat (arrhythmia). […] If you have Brugada syndrome but no symptoms, you may not need specific treatment because the risk of a serious irregular heartbeat is likely low. However, a health care provider might recommend taking steps to reduce the risk of irregular heartbeats. […] Some people with Brugada syndrome are prescribed medications, such as quinidine, to prevent a potentially dangerous heart rhythm. These drugs may be prescribed alone or with a medical device called an implantable cardioverter-defibrillator (ICD) that controls the heartbeat. […] People with Brugada syndrome who’ve had cardiac arrest or a worrisome fainting episode may need surgery or a catheter procedure.

• #1 Brugada Syndrome Treatment & Management: Approach Considerations, Placement of Implantable Cardioverter-Defibrillator, Activity

  https://emedicine.medscape.com/article/163751-treatment

  To date, the only treatment that has proven effective in treating ventricular tachycardia and fibrillation and preventing sudden death in patients with Brugada syndrome is implantation of an automatic implantable cardiac defibrillator (ICD). […] Radiofrequency catheter ablation has been recently reported as an effective new treatment. […] No pharmacologic therapy has been proved to reduce the occurrence of ventricular arrhythmias or sudden death. […] At present, implantation of an automatic implantable cardioverter-defibrillator (ICD) is the only treatment proved effective in treating ventricular tachycardia and fibrillation and preventing sudden death in patients with Brugada syndrome. […] Patients with Brugada syndrome and a history of cardiac arrest must be treated with an ICD. […] In contrast, asymptomatic patients with no family history of sudden cardiac death can be managed conservatively with close follow-up, and ICD implantation is not recommended.

• #1 Current Controversies and Challenges in Brugada Syndrome | ECR Journal

  https://www.ecrjournal.com/articles/current-controversies-and-challenges-brugada-syndrome?language_content_entity=en

  The mainstay of treatment in high-risk patients remains ICD implantation. Important risk-reducing strategies for all patients include avoiding excessive alcohol intake, immediate treatment of fever with antipyretics as well as avoidance of potentially aggravating medications. […] Treatment with quinidine can be considered as an adjunct to ICD in patients experiencing electrical storms or frequent appropriate shocks, or as an alternative to ICD in patients with contraindications to implantation. Quinidine reduces the Ito current during epicardial repolarisation and normalises the action potential and prevent re-entry and polymorphic VT formation in experimental models. […] The efficacy of quinidine monotherapy in long-term prevention of malignant ventricular arrhythmias after ICD implantation has been demonstrated in multiple studies.

• #1 Brugada syndrome

  https://www.nhs.uk/conditions/brugada-syndrome/

  If you have Brugada syndrome but you’ve not had any symptoms, you will not usually need any medical treatment. Most people with the condition have a low risk of serious problems. […] Doctors may recommend that you’re fitted with an implantable cardioverter defibrillator (ICD). […] You’ll only need an ICD if either: you’ve had symptoms such as a cardiac arrest, heart palpitations or fainting or doctors think you’re at high risk of getting a dangerous heart rhythm based on your electrocardiogram (ECG) results. […] If you have Brugada syndrome it’s important to avoid triggers that can cause problems with your heart rhythm. Your care team will give you advice about this.

• #1 Management of patients with a Brugada ECG pattern

  https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-7/Management-of-patients-with-a-Brugada-ECG-pattern

  Step 5: Treatment recommendations for BS patients […] a) ICD To date, the only proven effective therapeutic strategy for the prevention of SCD in BS patients is the ICD. It is important to remark that these patients present a considerably high rate of inappropriate shocks (20%-36% at 21-47 months follow-up), mostly due to sinus tachycardia, supraventricular tachyarrhythmias and lead complications; emphasising the importance of a careful ICD programming. […] b) Pharmacological treatment is under study. : Genetic basis and pathophysiology of BS-Rationale for pharmacological treatment. As a result of exhaustive investigation on the subject, some of the genetic basis and pathophysiologic substrate of arrhythmias in BS have been unravelled. […] Quinidine and Ito and I-Kr inhibitor have shown to prevent induction of VF and suppress spontaneous ventricular arrhythmias in a clinical setting, currently being used on patients with ICD and multiple shocks cases in which ICD implantation is contraindicated, or for the treatment of supraventricular arrhythmias. […] Isoproterenol (which increases the ICaL current) in combination with quinidine has proved to be useful for the treatment of electrical storms in BS. […] Other drugs being evaluated for BS are tedisamile, phosphodiesterase III inhibitors (cilostazol) and dimethyl lithospermate B.

• #1 Pharmacological Therapy in Brugada Syndrome

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6020192/

  Brugada syndrome (BrS) is a cardiac disease caused by an inherited ion channelopathy associated with a propensity to develop ventricular fibrillation. Implantable cardioverter defibrillator implantation is recommended in BrS, based on the clinical presentation in the presence of diagnostic ECG criteria. Implantable cardioverter defibrillator implantation is not always indicated or sufficient in BrS, and is associated with a high device complication rate. Pharmacological therapy aimed at rebalancing the membrane action potential can prevent arrhythmogenesis in BrS. Quinidine, a class 1A antiarrhythmic drug with significant Ito blocking properties, is the most extensively used drug for the prevention of arrhythmias in BrS. […] A pharmacological therapy approach aimed at rebalancing the epicardial action potential in the right ventricle and normalising the action potential dome can prevent arrhythmogenesis in BrS, unlike a device therapy approach, which addresses only the symptoms of BrS without preventing the arrhythmias from occurring. Drug therapy in BrS has several utilities: first, in the acute management of arrhythmic storm; second, in prevention of arrhythmic events in patients with implanted ICD who require many shocks; and third, as an alternative to ICD implantation when the latter is contraindicated, not feasible (infants and young children), unaffordable, or refused by the patient.

• #1 Current Controversies and Challenges in Brugada Syndrome | ECR Journal

  https://www.ecrjournal.com/articles/current-controversies-and-challenges-brugada-syndrome?language_content_entity=en

  One substantial problem with quinidine therapy used as an alternative to ICD implantation is the issue of poor adherence and treatment discontinuation or interruption due to associated adverse effects, most commonly gastrointestinal. […] Radiofrequency ablation (RFA) of arrhythmogenic zones in the right ventricular epicardium has emerged over the past decade as a possible future curative treatment option for Brugada syndrome. […] RFA treatment is therefore recommended for symptomatic patients with recurrent ICD shocks or as an alternative to ICD implantation when contraindicated.

• #1 Brugada syndrome – Diagnosis & treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/brugada-syndrome/diagnosis-treatment/drc-20370494

  Implantable cardioverter-defibrillator (ICD). This small, battery-operated device is placed in the chest to continuously monitor the heart rhythm. It delivers electrical shocks when needed to control irregular heartbeats. […] If an ICD doesn’t effectively and safely control Brugada syndrome symptoms, a procedure called radiofrequency catheter ablation may be an option. A long, flexible tube (catheter) is inserted through a blood vessel and threaded to the heart. The catheter delivers high energy that scars or destroys the heart tissue responsible for the irregular heart rhythm. […] If you have Brugada syndrome, you need regular health checkups to make sure the heart rhythm disorder is properly managed and controlled. Regular checkups can help your provider detect complications early and determine if a treatment change is needed.

• #1 Recent advances in the treatment of Brugada syndrome

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6330094/

  Implantation of a cardioverter defibrillator (ICD) is first-line therapy for BrS patients presenting with prior cardiac arrest or documented VT. […] A pharmacological approach to therapy is recommended in cases of electrical storm, as an adjunct to ICD and as preventative therapy. […] Understanding of the pathophysiology and approach to therapy of BrS has advanced considerably in recent years, but there remains an urgent need for development of cardio-selective and ion-channel-specific drugs for treatment of BrS. […] The implantation of an implantable cardioverter defibrillator (ICD) is accepted as first line therapy for prevention of SCD in high risk BrS. […] Radiofrequency ablation of epicardial sites displaying late potentials and fractionated bipolar electrograms (EGs) in the RVOT of BrS patients can significantly reduce arrhythmia vulnerability and the ECG manifestation of the disease.

• #1 Brugada syndrome: a review and the role of epicardial ablation in management | The Egyptian Heart Journal | Full Text

  https://tehj.springeropen.com/articles/10.1186/s43044-024-00485-3

  Recent studies have highlighted the presence of epicardial fibrosis as a proarrhythmic substrate in BrS, revolutionizing our understanding of the disease’s pathophysiology. Catheter ablation has emerged as a crucial intervention for symptomatic BrS patients experiencing recurrent episodes of ventricular tachycardia (VT) or VF. By potentially obviating the need for implantable cardioverterdefibrillator (ICD) implantation, epicardial ablation offers a promising therapeutic approach. […] The management of patients with BrS poses significant challenges due to the complex nature of the condition. Implantable cardioverterdefibrillators (ICDs) play a crucial role in preventing sudden cardiac death and are recommended for specific patient groups. According to the guidelines, ICD implantation is considered a Class I indication for patients with BrS and a history of prior cardiac arrest. Furthermore, individuals with BrS who exhibit a spontaneous type I electrocardiographic pattern and experience recurrent syncope are also candidates for ICD placement.

• #1 Brugada Syndrome: Evolving Insights and Emerging Treatment Strategies

  https://www.innovationsincrm.com/cardiac-rhythm-management/articles-2017/february/983-brugada-syndrome

  Although the results of substrate-based catheter ablation have been extremely promising, arrhythmic recurrences have been reported despite normalization of the ECG. Notably, it appears that although the type 1 ECG pattern was no longer present spontaneously in these patients, it could still be induced with drug provocation. This realization led to the mapping of the RVOT epicardium in the presence of sodium channel blockade, which resulted in the identification of larger regions with fractionated and late potentials that could be targeted with ablation. This approach, which appears to permit for a more complete identification of the BrS arrhythmogenic substrate, has resulted in improved long-term clinical results, and will hopefully be sufficient to overcome prior treatment failures. In order to further clarify the efficacy of catheter ablation, a randomized controlled trial, called the Ablation in Brugada Syndrome for Prevention of VF (BRAVE) study, is being initiated. BrS patients who have suffered an ICD shock will be randomized to either receive catheter ablation or no additional therapy, and will be followed for up to three years for recurrent malignant arrhythmias.

• #1 BrugadaDrugs.org | Safe drug use and the Brugada syndrome

  https://www.brugadadrugs.org/

  Brugada syndrome is diagnosed in the presence of specific electrocardiographic abnormalities (known as the type-1 Brugada syndrome ECG) combined with an absence of gross structural abnormalities and several other criteria. […] Therefore, it is necessary to advise patients with Brugada syndrome not to use these drugs, or to do so only in controlled conditions so that its potential pro-arrhythmic effect or the lack thereof can be documented and treated if necessary. […] It should be seriously considered to advise patients with Brugada syndrome to avoid drugs from the Red list (drugs to be avoided) because these drugs might result in arrhythmias, or to use these drugs only after extensive consideration and/or in controlled conditions. […] However, avoidance of (potential) proarrhythmic drugs and fever (a well known trigger of cardiac events in Brugada syndrome) is generally accepted to be an important part of (prophylactic) treatment. […] However, some patients may be appropriately treated with an implantable cardioverter defibrillator with or without ablation therapy. […] Furthermore, many Brugada syndrome patients seem to perform well on quinidine.

• #1 Brugada Syndrome – Melbourne Heart Rhythm

  https://www.melbourneheartrhythm.com.au/learn/conditions/52-brugada-syndrome

  As the changes of Brugada Syndrome on ECG are unmasked by febrile states, aggressive treatment of all febrile episodes is recommended with antipyretics like aspirin and paracetamol and cold sponges, large carbohydrate meals and alcohol and very hot baths have also been incriminated and should be avoided. […] Drugs that can cause Brugada-like changes on the ECG are best avoided and include: Class 1 antiarrhythmic drugs like flecainide, beta and alpha adrenergic blockers, channel blockers like verapamil, diltiazem, nifedipine, nitrates, potassium channel openers like nicorandil, tricyclic and tetracyclic antidepressants, phenothiazines and antidepressants like fluoxetine. Alcohol and cocaine can cause dangerous heart rhythms in patients with Brugada Syndrome. […] A drug called Quinidine is used in Brugada Syndrome patients who have repeated ICD shocks or an 'arrhythmic storm’. Unfortunately, this old drug is now difficult to get and is only available under the special access scheme in Australia. Intravenous Isoprenaline (a form of adrenaline) is also helpful in the emergency treatment of arrhythmic storms in Brugada Syndrome.

• #1 Brugada syndrome: ECG, clinical features and management – The Cardiovascular

  https://ecgwaves.com/topic/brugada-syndrome-ecg-treatment-type-1-2-3/

  Some minor lifestyle changes are warranted. Excessive alcohol consumption is believed to be pro-arrhythmic and should therefore be avoided. The patient must not use any medication which may induce arrhythmias; the list of these drugs is extensive and a continuously updated list is available at www.brugadadrugs.org/drug-lists/. […] Prospective studies show that the use of ICD may be highly beneficial in selected cases of Brugada syndrome. The ICD prevents sudden cardiac death och thus increases survival. However, ICD is not indicated in individuals with asymptomatic Brugada syndrome (regardless of ECG pattern) because the risk of sudden cardiac arrest is very low. […] An ICD should be considered in the following situations: Patients who have survived cardiac arrest should have an ICD. Patients with documented sustained ventricular tachycardia should have an ICD implanted. Patients with type 1 Brugada ECG and a history of syncope may benefit from an ICD. An ICD should be considered. Patients with inducible ventricular fibrillation during invasive provocation (stimulation during electrophysiological study) may benefit from an ICD. An ICD should be considered.

• #1 Brugada Syndrome Treatment & Management: Approach Considerations, Placement of Implantable Cardioverter-Defibrillator, Activity

  https://emedicine.medscape.com/article/163751-treatment

  Patients with syncope or cardiac arrest and suspected or diagnosed Brugada syndrome must be hospitalized. Continuous cardiac monitoring is necessary until definitive treatment (ie, ICD placement) can be provided. […] A board-certified cardiologist who specializes in cardiac arrhythmic disorders (ie, a clinical electrophysiologist) should evaluate patients with suspected Brugada syndrome. […] Consultation with a genetic counselor is indicated for genetic screening and counseling of patients and their relatives. […] A board-certified electrophysiologist should closely follow patients with Brugada syndrome.

• #1 Brugada Syndrome: Evolving Insights and Emerging Treatment Strategies

  https://www.innovationsincrm.com/cardiac-rhythm-management/articles-2017/february/983-brugada-syndrome

  The S-ICD is a new treatment option that appears to be ideally suited for patients with BrS given its ability to avoid the pitfalls associated with long-term use of transvenous lead systems, coupled with the fact that intracardiac pacing is rarely required in BrS patients. It is conceivable that the alternate benefit-risk profile of the S-ICD may permit a more aggressive approach to management in asymptomatic patients with high risk features who are currently being managed conservatively, owing to concerns for adverse events associated with transvenous devices. Although avoiding a transvenous device is appealing, it should be noted that there may be a comparable risk of non-lead-related complications over a lifetime. As such, larger studies with longer-term follow-up will be necessary to further clarify relative benefits of S-ICD therapy in this patient population. One important consideration for S-ICD use in BrS patients is the potential need to perform vector testing to evaluate the patients suitability for implantation during drug challenge, when the type 1 ECG pattern is transient. […]

• #1 Gene therapy for Brugada syndrome | Nature Reviews Cardiology

  https://www.nature.com/articles/s41569-022-00744-3

  A novel mouse model of Brugada syndrome (BrS) is used to demonstrate that gene therapy targeting the protein trafficking regulator MOG1 (also known as RAN guanine nucleotide release factor) can successfully reverse the cardiac functional abnormalities associated with BrS. […] Patients with BrS, an inherited arrhythmia syndrome characterized by ventricular tachycardia (VT) or fibrillation, have limited treatment options. […] The researchers subsequently used the mouse model to test the efficacy of gene therapy for BrS.

• #1 Brugada Syndrome: Symptoms & Treatment

  https://my.clevelandclinic.org/health/diseases/16813-brugada-syndrome

  The goal of Brugada syndrome treatment is to keep you from having ventricular arrhythmias and treat them when they happen. […] Your treatment may include: Isoproterenol. […] Implantable cardioverter defibrillator (ICD) if you have ventricular tachycardia, fainting spells or a cardiac arrest. […] If you’re not having symptoms, your provider may decide you need an ICD because of your family history or test results. […] People with Brugada syndrome who have symptoms but aren’t receiving treatment have a high risk of sudden cardiac death. […] There’s no cure for Brugada syndrome. But treatments can lower your risk for sudden cardiac death, which is a complication of Brugada syndrome.

• #2 Brugada Syndrome: Symptoms & Treatment

  https://my.clevelandclinic.org/health/diseases/16813-brugada-syndrome

  The goal of Brugada syndrome treatment is to keep you from having ventricular arrhythmias and treat them when they happen. […] Your treatment may include: Isoproterenol. […] Implantable cardioverter defibrillator (ICD) if you have ventricular tachycardia, fainting spells or a cardiac arrest. […] If you’re not having symptoms, your provider may decide you need an ICD because of your family history or test results. […] People with Brugada syndrome who have symptoms but aren’t receiving treatment have a high risk of sudden cardiac death. […] There’s no cure for Brugada syndrome. But treatments can lower your risk for sudden cardiac death, which is a complication of Brugada syndrome.

• #2 Brugada syndrome – Diagnosis & treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/brugada-syndrome/diagnosis-treatment/drc-20370494

  Implantable cardioverter-defibrillator (ICD). This small, battery-operated device is placed in the chest to continuously monitor the heart rhythm. It delivers electrical shocks when needed to control irregular heartbeats. […] If an ICD doesn’t effectively and safely control Brugada syndrome symptoms, a procedure called radiofrequency catheter ablation may be an option. A long, flexible tube (catheter) is inserted through a blood vessel and threaded to the heart. The catheter delivers high energy that scars or destroys the heart tissue responsible for the irregular heart rhythm. […] If you have Brugada syndrome, you need regular health checkups to make sure the heart rhythm disorder is properly managed and controlled. Regular checkups can help your provider detect complications early and determine if a treatment change is needed.

• #2 Recent advances in the treatment of Brugada syndrome

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6330094/

  Implantation of a cardioverter defibrillator (ICD) is first-line therapy for BrS patients presenting with prior cardiac arrest or documented VT. […] A pharmacological approach to therapy is recommended in cases of electrical storm, as an adjunct to ICD and as preventative therapy. […] Understanding of the pathophysiology and approach to therapy of BrS has advanced considerably in recent years, but there remains an urgent need for development of cardio-selective and ion-channel-specific drugs for treatment of BrS. […] The implantation of an implantable cardioverter defibrillator (ICD) is accepted as first line therapy for prevention of SCD in high risk BrS. […] Radiofrequency ablation of epicardial sites displaying late potentials and fractionated bipolar electrograms (EGs) in the RVOT of BrS patients can significantly reduce arrhythmia vulnerability and the ECG manifestation of the disease.

• #2 Management of patients with a Brugada ECG pattern

  https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-7/Management-of-patients-with-a-Brugada-ECG-pattern

  Step 5: Treatment recommendations for BS patients […] a) ICD To date, the only proven effective therapeutic strategy for the prevention of SCD in BS patients is the ICD. It is important to remark that these patients present a considerably high rate of inappropriate shocks (20%-36% at 21-47 months follow-up), mostly due to sinus tachycardia, supraventricular tachyarrhythmias and lead complications; emphasising the importance of a careful ICD programming. […] b) Pharmacological treatment is under study. : Genetic basis and pathophysiology of BS-Rationale for pharmacological treatment. As a result of exhaustive investigation on the subject, some of the genetic basis and pathophysiologic substrate of arrhythmias in BS have been unravelled. […] Quinidine and Ito and I-Kr inhibitor have shown to prevent induction of VF and suppress spontaneous ventricular arrhythmias in a clinical setting, currently being used on patients with ICD and multiple shocks cases in which ICD implantation is contraindicated, or for the treatment of supraventricular arrhythmias. […] Isoproterenol (which increases the ICaL current) in combination with quinidine has proved to be useful for the treatment of electrical storms in BS. […] Other drugs being evaluated for BS are tedisamile, phosphodiesterase III inhibitors (cilostazol) and dimethyl lithospermate B.

• #2 Brugada syndrome: ECG, clinical features and management – The Cardiovascular

  https://ecgwaves.com/topic/brugada-syndrome-ecg-treatment-type-1-2-3/

  Some minor lifestyle changes are warranted. Excessive alcohol consumption is believed to be pro-arrhythmic and should therefore be avoided. The patient must not use any medication which may induce arrhythmias; the list of these drugs is extensive and a continuously updated list is available at www.brugadadrugs.org/drug-lists/. […] Prospective studies show that the use of ICD may be highly beneficial in selected cases of Brugada syndrome. The ICD prevents sudden cardiac death och thus increases survival. However, ICD is not indicated in individuals with asymptomatic Brugada syndrome (regardless of ECG pattern) because the risk of sudden cardiac arrest is very low. […] An ICD should be considered in the following situations: Patients who have survived cardiac arrest should have an ICD. Patients with documented sustained ventricular tachycardia should have an ICD implanted. Patients with type 1 Brugada ECG and a history of syncope may benefit from an ICD. An ICD should be considered. Patients with inducible ventricular fibrillation during invasive provocation (stimulation during electrophysiological study) may benefit from an ICD. An ICD should be considered.

• #2 The Benefits and Risks of ICD Therapy in Brugada Syndrome

  https://www.thecardiologyadvisor.com/news/the-benefits-and-risks-of-icd-therapy-in-brugada-syndrome/

  Patients with Brugada syndrome that receive ICD therapy have decreased risk for fatal arrhythmias. […] Implantable cardioverter-defibrillator (ICD) therapy is effective for preventing fatal arrhythmias in patients with Brugada syndrome, although device-related complications are common, according to results of a study in JACC: Clinical Electrophysiology. […] Before ICD implantation, physicians should thoroughly explain to Brugada syndrome patients both the potential benefits of the device and the risks associated with device-related complications. […] Before ICD implantation, physicians should thoroughly explain to Brugada syndrome patients both the potential benefits of the device and the risks associated with device-related complications, the investigators wrote.

• #2 Recent advances in the treatment of Brugada syndrome

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6330094/

  A pharmacologic approach to therapy is recommended in the case of electrical storms, as an adjunct to ICD and as preventative therapy for asymptomatic patients at risk for the development of life-threatening arrhythmic events. […] The principal goal of therapy is to produce an inward shift in the balance of currents. […] Quinidine is effective in restoring the epicardial action potential dome and normalizing the ST segment, thus preventing the development of phase 2 reentry and polymorphic VT. […] The development of a more cardio-selective and Ito-specific blocker would be a most welcome addition to the limited therapeutic armamentarium currently available to combat this disease. […] Anti-androgen therapy may prove helpful in severe cases, pending further clinical evidence in support of this approach.

• #2 Pharmacological Therapy in Brugada Syndrome

  https://pmc.ncbi.nlm.nih.gov/articles/PMC6020192/

  Quinidine is the most extensively studied medication with proven efficacy in successfully controlling and preventing arrhythmic events in BrS. It is the authors opinion that this medication is an alternative to ICD therapy in all types of BrS patients who have fulfilled the strict conditions detailed elsewhere.

• #2 Brugada Syndrome – Melbourne Heart Rhythm

  https://www.melbourneheartrhythm.com.au/learn/conditions/52-brugada-syndrome

  As the changes of Brugada Syndrome on ECG are unmasked by febrile states, aggressive treatment of all febrile episodes is recommended with antipyretics like aspirin and paracetamol and cold sponges, large carbohydrate meals and alcohol and very hot baths have also been incriminated and should be avoided. […] Drugs that can cause Brugada-like changes on the ECG are best avoided and include: Class 1 antiarrhythmic drugs like flecainide, beta and alpha adrenergic blockers, channel blockers like verapamil, diltiazem, nifedipine, nitrates, potassium channel openers like nicorandil, tricyclic and tetracyclic antidepressants, phenothiazines and antidepressants like fluoxetine. Alcohol and cocaine can cause dangerous heart rhythms in patients with Brugada Syndrome. […] A drug called Quinidine is used in Brugada Syndrome patients who have repeated ICD shocks or an 'arrhythmic storm’. Unfortunately, this old drug is now difficult to get and is only available under the special access scheme in Australia. Intravenous Isoprenaline (a form of adrenaline) is also helpful in the emergency treatment of arrhythmic storms in Brugada Syndrome.

• #2 Current Controversies and Challenges in Brugada Syndrome | ECR Journal

  https://www.ecrjournal.com/articles/current-controversies-and-challenges-brugada-syndrome?language_content_entity=en

  One substantial problem with quinidine therapy used as an alternative to ICD implantation is the issue of poor adherence and treatment discontinuation or interruption due to associated adverse effects, most commonly gastrointestinal. […] Radiofrequency ablation (RFA) of arrhythmogenic zones in the right ventricular epicardium has emerged over the past decade as a possible future curative treatment option for Brugada syndrome. […] RFA treatment is therefore recommended for symptomatic patients with recurrent ICD shocks or as an alternative to ICD implantation when contraindicated.

• #2 Brugada Syndrome: Focus for the General Pediatrician

  https://www.mdpi.com/2227-9067/11/3/281

  An implantable cardioverter defibrillator is strongly recommended (Class of Recommendation I, Level of evidence A) in secondary prevention (patients with a history of cardiac arrest), as these subjects are at high risk of developing further malignant arrhythmic events. In subjects with one or more major risk factors, especially with a history of syncope of probable cardiogenic origin, the implantation of a cardiac defibrillator in primary prevention is recommended in class IIA. […] Pharmacological therapy may include using quinidine, a class I antiarrhythmic, which can normalize the ECG tracing and reduce the risk of VF and sustained VT. However, it has a pro-arrhythmic potential and significant dose-related side effects (diarrhea, thrombocytopenia, anemia, neurological effects), which make its long term use difficult. […] In patients with persistent arrhythmic episodes despite optimized drug therapy or in those intolerant to quinidine, radiofrequency ablation may be considered to eliminate the arrhythmogenic substrate located at the RVOT.

• #2 Therapy for the Brugada Syndrome | SpringerLink

  https://link.springer.com/chapter/10.1007/3-540-29715-4_12

  The Brugada syndrome is a congenital syndrome of sudden cardiac death first described as a new clinical entity in 1992. […] An implantable cardioverter-defibrillator (ICD) is the most widely accepted approach to therapy. […] Pharmacological therapy aimed at rebalancing the currents active during phase 1 of the right ventricular action potential is used to abort electrical storms, as an adjunct to device therapy, and as an alternative to device therapy when use of an ICD is not possible. […] Isoproterenol and cilostazol boost calcium channel current, and drugs like quinidine inhibit the transient outward current, acting to diminish the action potential notch and thus suppress the substrate and trigger for ventricular tachycardia/fibrillation (VT/VF).

• #2 Brugada Syndrome Treatment & Management: Approach Considerations, Placement of Implantable Cardioverter-Defibrillator, Activity

  https://emedicine.medscape.com/article/163751-treatment

  To date, the only treatment that has proven effective in treating ventricular tachycardia and fibrillation and preventing sudden death in patients with Brugada syndrome is implantation of an automatic implantable cardiac defibrillator (ICD). […] Radiofrequency catheter ablation has been recently reported as an effective new treatment. […] No pharmacologic therapy has been proved to reduce the occurrence of ventricular arrhythmias or sudden death. […] At present, implantation of an automatic implantable cardioverter-defibrillator (ICD) is the only treatment proved effective in treating ventricular tachycardia and fibrillation and preventing sudden death in patients with Brugada syndrome. […] Patients with Brugada syndrome and a history of cardiac arrest must be treated with an ICD. […] In contrast, asymptomatic patients with no family history of sudden cardiac death can be managed conservatively with close follow-up, and ICD implantation is not recommended.

• #2 Brugada syndrome: a review and the role of epicardial ablation in management | The Egyptian Heart Journal | Full Text

  https://tehj.springeropen.com/articles/10.1186/s43044-024-00485-3

  In addition to ICD therapy, comprehensive management of BrS involves patient education and awareness. It is strongly recommended by the European Society of Cardiology (ESC) guidelines that all individuals diagnosed with BrS be educated about the factors that can modulate or precipitate arrhythmias and advised on how to avoid these triggers. […] In terms of pharmacological treatment, quinidine is currently the only known effective long-term therapy for BrS. It has demonstrated benefits in reducing arrhythmic events and is considered a viable option for patients who require medical intervention. […] The standard therapy for the prevention of SCD in BrS is an implantable cardioverterdefibrillator (ICD) in patients who have experienced a prior cardiac arrest or syncopal events. However, an ICD does not prevent the occurrence of VF but only terminates malignant ventricular arrhythmias. Anti-arrhythmic medications such as quinidine can be used to prevent malignant ventricular arrhythmias in BrS patients, but such medications are not well tolerated and are associated with side effects. Therefore, the need for an alternative therapy has led to attempts in using catheter ablation to treat the arrhythmogenic substrate of BrS.

• #2 Brugada Syndrome: Evolving Insights and Emerging Treatment Strategies

  https://www.innovationsincrm.com/cardiac-rhythm-management/articles-2017/february/983-brugada-syndrome

  Catheter ablation has also recently emerged as a compelling treatment option for BrS, particularly given its perceived potential to serve as a curative form of therapy. Initial attempts to treat BrS with catheter ablation have been reported by Haissaguerre and colleagues, who targeted triggers in the form of premature ventricular contractions from the RVOT endocardium. Although effective in a limited number of patients, the efficacy of the approach is limited by the fact that triggers in BrS are rarely observed. The substrate-based approach reported by Nademanee in 2011 instead targeted fractionated and late potentials identified along the RVOT epicardium for ablation, obviating the need for identifying triggers. Strikingly, in this study, the substrate-based approach led to the normalization of the surface ECG and the cessation of arrhythmic events among BrS patients who had been suffering from recurrent ICD shocks refractory to medical therapy. Since this initial report, similar results have been obtained in other, larger studies with longer follow-up. […]

• #2 Brugada syndrome: a review and the role of epicardial ablation in management | The Egyptian Heart Journal | Full Text

  https://tehj.springeropen.com/articles/10.1186/s43044-024-00485-3

  The use of catheter ablation has a very promising role in managing BrS patients; however, further studies are needed to assert its long-term benefit in preventing recurrent VF. Currently, the randomized controlled trial BRAVE is investigating the benefit of catheter ablation as a potential curative treatment strategy in patients with BrS. Meanwhile, catheter ablation can be used in patients with recurrent VT/VF in experienced centers and patients should be counseled about the risks associated with epicardial access and the potential arrhythmogenic effects of drug administration.

• #2 Brugada syndrome

  https://www.nhs.uk/conditions/brugada-syndrome/

  If you have Brugada syndrome but you’ve not had any symptoms, you will not usually need any medical treatment. Most people with the condition have a low risk of serious problems. […] Doctors may recommend that you’re fitted with an implantable cardioverter defibrillator (ICD). […] You’ll only need an ICD if either: you’ve had symptoms such as a cardiac arrest, heart palpitations or fainting or doctors think you’re at high risk of getting a dangerous heart rhythm based on your electrocardiogram (ECG) results. […] If you have Brugada syndrome it’s important to avoid triggers that can cause problems with your heart rhythm. Your care team will give you advice about this.

• #2 Brugada syndrome – Wikipedia

  https://en.wikipedia.org/wiki/Brugada_syndrome

  There is no cure for Brugada syndrome. Those at higher risk of sudden cardiac death may be treated using an implantable cardioverter defibrillator (ICD). […] In those without symptoms the risk of death is much lower, and how to treat this group is less clear. Isoproterenol may be used in the short term for those who have frequent life-threatening abnormal heart rhythms, while quinidine may be used longer term. […] The first line of treatment, suitable for all people with Brugada syndrome regardless of their risk of arrhythmias, is lifestyle advice. People should be advised to recognise and avoid things that may increase the risk of serious arrhythmias. These include avoiding excessive alcohol consumption, avoiding certain medications, and treating fever promptly with paracetamol. […] In people felt to be at higher risk of sudden cardiac death, an implantable cardioverter-defibrillator (ICD) may be recommended. […] Quinidine is an antiarrhythmic drug that may reduce the chance of serious abnormal heart rhythms occurring in some people with Brugada syndrome. […] A further treatment option for people with Brugada syndrome is radiofrequency catheter ablation.

• #2 Brugada syndrome treatment – wikidoc

  https://www.wikidoc.org/index.php/Brugada_syndrome_treatment

  Pharmacotherapy alone may not be sufficient to treat Brugada syndrome, but it may be required in regions of the world where ICD implantation is cost prohibitive or in infants. Quinidine reduces the number of VF episodes and corrects spontaneous ECG changes, possibly via inhibiting I(to) channels. No drug has demonstrated long term efficacy in the prevention of sudden cardiac death. […] VT storm has been successfully treated with isoproterenol. The mechanism is thought to be augmenting the cardiac L type channel. […] Patients with risk factors for coronary artery disease may require an angiogram before ICD implantation. […] Fever in a Brugada syndrome patient should be treated with an antipyretic. Brugada syndrome patients should avoid hot tubs, very hot baths or extremely hot climates. Hypokalemia, hyperkalemia, and hypercalcemia should be treated aggressively. Brugada syndrome carbohydrate loading should be avoided. […] In patients with Brugada syndrome with spontaneous type 1 Brugada electrocardiographic pattern and cardiac arrest, sustained VA or a recent history of syncope presumed due to VA, an ICD is recommended if meaningful survival of greater than 1 year is expected.

• #2 Brugada syndrome treatment – wikidoc

  https://www.wikidoc.org/index.php/Brugada_syndrome_treatment

  Implantation of a cardiac defibrillator is the only proven method of treatment in Brugada syndrome. Patients with aborted sudden cardiac death are at high risk for recurrence and should undergo AICD implantation, and do not require an electrophysiologic study to assess inducibility. Patients with symptoms (either syncope, seizures or nocturnal agonal respirations) should undergo implantation of a defibrillator if no other cause of their symptoms can be identified. Asymptomatic patients should undergo electrophysiologic testing, and if VT / VF can be induced, they should undergo implantation of an ICD. Asymptomatic patients who cannot be induced should followed-up closely. Patients who are asymptomatic with no family history of Brugada syndrome can be followed-up closely. […] Implantation of a cardiac defibrillator should be considered in the following patients: Patients with aborted sudden cardiac death, Patients with syncope, seizures or nocturnal agonal respirations who have no other identifiable cause for their symptoms.

• #2 Brugada syndrome | Beacon Health System

  https://www.beaconhealthsystem.org/library/diseases-and-conditions/brugada-syndrome?content_id=CON-20370473

  People with Brugada syndrome who’ve had cardiac arrest or a worrisome fainting episode may need surgery or a catheter procedure. […] Implantable cardioverter-defibrillator (ICD). This small, battery-operated device is placed in the chest to continuously monitor the heart rhythm. It delivers electrical shocks when needed to control irregular heartbeats. ICD placement usually requires an overnight hospital stay. […] Catheter ablation. If an ICD doesn’t effectively and safely control Brugada syndrome symptoms, a procedure called radiofrequency catheter ablation may be an option. A long, flexible tube (catheter) is inserted through a blood vessel and threaded to the heart. The catheter delivers high energy that scars or destroys the heart tissue responsible for the irregular heart rhythm. […] If you have Brugada syndrome, you need regular health checkups to make sure the heart rhythm disorder is properly managed and controlled. Regular checkups can help your provider detect complications early and determine if a treatment change is needed.

• #2 Brugada Syndrome (BrS) – AF-ABLATION

  https://af-ablation.org/en/arrhythmological-disorders/brugada-syndrome-brs/

  WHAT ARE THE TREATMENTS RECOMMENDED FOR BRUGADA SYNDROME? Once the diagnosis of BrS is made, the therapeutic approach depends on the patients level of risk. Brugada syndrome does not present with a definite clinical progression, and therefore a patient may experience new clinical elements indicative of a possible change in the level of risk. Therefore, it is appropriate to carry out checks every six months. Currently the therapeutic options available for Brugada syndrome are essentially of three types: Implantation of cardiac defibrillator (ICD, intracavitary or subcutaneous) or implantable cardiac monitors (subcutaneous ICM or loop recorder) […] Transcatheter epicardial ablation of the arrhythmic substrate […] Drug therapy with specific antiarrhythmic drugs (Quinidine). […] WHEN TO USE THE CARDIAC DEFIBRILLATOR (ICD) AND CARDIAC MONITOR (ICM) SYSTEM IN BRUGADA SYNDROME? ICD is the only therapy with proven efficacy in preventing sudden arrhythmic cardiac death. The implantation of a defibrillator is necessary in the event of a finding of BrS that presents with high risk characteristics.

• #2 Brugada syndrome — Knowledge Hub

  https://www.genomicseducation.hee.nhs.uk/genotes/knowledge-hub/brugada-syndrome/

  The mainstay of treatment in Brugada syndrome is careful lifestyle advice. Certain drugs may increase the likelihood of arrhythmia in the setting of Brugada syndrome. Patients should be directed to BrugadaDrugs.org for the list of drugs to avoid. Affected individuals should be given advice regarding prompt treatment of fever with antipyretics (such as paracetamol and ibuprofen) due to increased risk of arrhythmia. During a diarrhoea and vomiting illness, affected individuals should keep well hydrated using oral rehydration therapy (such as Dioralyte). Affected individuals should also be advised to avoid excessive alcohol consumption, cocaine and cannabis use and eating large meals before bed due to increased risk of arrhythmia. […] Implantable cardioverter-defibrillator (ICD) implantation is recommended in individuals who have survived cardiac arrest or have documented episodes of spontaneous ventricular arrhythmia. ICD implantation should be considered in individuals with a spontaneous type 1 Brugada ECG pattern and syncope. Asymptomatic affected individuals may undergo electrophysiology studies to assess whether there is inducible ventricular tachycardia or ventricular fibrillation. Affected individuals with recurrent ventricular arrhythmias may be treated using medication (such as quinidine) or with catheter ablation. Individuals with Brugada syndrome should be considered for genomic counselling (see the National Genomic Test Directory for eligibility criteria).

• #3 Brugada Syndrome: Focus for the General Pediatrician

  https://www.mdpi.com/2227-9067/11/3/281

  The therapeutic approach depends on the patient’s risk of developing life-threatening arrhythmias, it is advisable to perform a close follow-up in these patients to identify any new arrhythmic risk factors early. […] Recommendations for the treatment of Brugada Syndrome are generally extrapolated from the adult population, with often weak or virtually absent indications for pediatric age. It must be underlined that arrhythmic risk before 12–15 years of age is generally low; therefore, treatment recommendations should be weighted case by case, not forgetting the possible serious adverse events related to some therapies (i.e., potential arrhythmic risk of quinidine or possible complications of an implantable cardioverter defibrillator, like inappropriate shocks and infections). […] The only treatment effective in controlling ventricular arrhythmias and preventing sudden cardiac death is the implantation of the cardiac defibrillator. However, the use of this device is burdened by numerous adverse effects such as inappropriate shocks, malfunction of the electrodes, risk of infections resulting in the need for removal and substitution of the device, and the difficulty of acceptance by the patient.

• #3 Brugada syndrome treatment – wikidoc

  https://www.wikidoc.org/index.php/Brugada_syndrome_treatment

  Implantation of a cardiac defibrillator is the only proven method of treatment in Brugada syndrome. Patients with aborted sudden cardiac death are at high risk for recurrence and should undergo AICD implantation, and do not require an electrophysiologic study to assess inducibility. Patients with symptoms (either syncope, seizures or nocturnal agonal respirations) should undergo implantation of a defibrillator if no other cause of their symptoms can be identified. Asymptomatic patients should undergo electrophysiologic testing, and if VT / VF can be induced, they should undergo implantation of an ICD. Asymptomatic patients who cannot be induced should followed-up closely. Patients who are asymptomatic with no family history of Brugada syndrome can be followed-up closely. […] Implantation of a cardiac defibrillator should be considered in the following patients: Patients with aborted sudden cardiac death, Patients with syncope, seizures or nocturnal agonal respirations who have no other identifiable cause for their symptoms.

• #3 Brugada Syndrome: Evolving Insights and Emerging Treatment Strategies

  https://www.innovationsincrm.com/cardiac-rhythm-management/articles-2017/february/983-brugada-syndrome

  Current therapeutic options are relatively limited for BrS, with ICD therapy being the only proven treatment strategy for the prevention of SCD. Expert consensus guidelines currently recommend ICD therapy as a class 1 indication for patients with prior cardiac arrest or documented polymorphic VT, whereas a spontaneous type 1 ECG pattern with a history suggesting arrhythmic syncope is a class IIa indication. Although effective for preventing SCD, ICD implantation also carries a significant risk of complications over the patients lifetime, particularly if the patient is younger at the time of insertion. Beyond a high prevalence of inappropriate shocks, ICD implantation at a young age also exposes patients to recurrent risks of infection secondary to pulse generator changes and inevitable lead complications that often necessitate subsequent extraction procedures that carry a risk of death. […]

• #3 Brugada Syndrome Medication: Antiarrhythmic Drugs

  https://emedicine.medscape.com/article/163751-medication

  Theoretically, drugs that counteract the ionic current imbalance in Brugada syndrome could be used to treat it. For example, quinidine, which blocks the calcium-independent transient outward potassium current (Ito), has been shown to normalize the ECG pattern in patients with Brugada syndrome. […] Thus far, no drug therapy for Brugada syndrome is recommended because clinical trials have failed to convincingly prove effectiveness. […] However, drugs such as isoproterenol can be used to treat VT storm. Quinidine can be used for patients who have recurrent appropriate ICD therapy. […] Currently, quinidine seems to be the treatment of choice for long-term therapy.

• #3 Brugada Syndrome – Diagnosis and Treatment : Emergency Care BC

  https://emergencycarebc.ca/clinical_resource/clinical-summary/brugada-syndrome-diagnosis-and-treatment/

  Recommended Treatment […] Symptomatic patients are at high risk of a SAE, and the only proven therapy is an ICD. […] Quinidine is the only pharmacologic agent that has been able to demonstrate prevention of BrS arrhythmias. It is not a first line option due to limited evidence and a large side effect profile. […] Amiodarone is not an effective agent to control BrS arrhythmias. It has been shown to unmask Brugada ECG patterns and aggravate episodes of ventricular fibrillation. […] Isoproterenol should be used in BrS patients experiencing electrical storms and acute recurrences of ventricular fibrillation (VF).

• #3 Brugada Syndrome: Evolving Insights and Emerging Treatment Strategies

  https://www.innovationsincrm.com/cardiac-rhythm-management/articles-2017/february/983-brugada-syndrome

  Although the results of substrate-based catheter ablation have been extremely promising, arrhythmic recurrences have been reported despite normalization of the ECG. Notably, it appears that although the type 1 ECG pattern was no longer present spontaneously in these patients, it could still be induced with drug provocation. This realization led to the mapping of the RVOT epicardium in the presence of sodium channel blockade, which resulted in the identification of larger regions with fractionated and late potentials that could be targeted with ablation. This approach, which appears to permit for a more complete identification of the BrS arrhythmogenic substrate, has resulted in improved long-term clinical results, and will hopefully be sufficient to overcome prior treatment failures. In order to further clarify the efficacy of catheter ablation, a randomized controlled trial, called the Ablation in Brugada Syndrome for Prevention of VF (BRAVE) study, is being initiated. BrS patients who have suffered an ICD shock will be randomized to either receive catheter ablation or no additional therapy, and will be followed for up to three years for recurrent malignant arrhythmias.

• #3 Brugada syndrome — Knowledge Hub

  https://www.genomicseducation.hee.nhs.uk/genotes/knowledge-hub/brugada-syndrome/

  The mainstay of treatment in Brugada syndrome is careful lifestyle advice. Certain drugs may increase the likelihood of arrhythmia in the setting of Brugada syndrome. Patients should be directed to BrugadaDrugs.org for the list of drugs to avoid. Affected individuals should be given advice regarding prompt treatment of fever with antipyretics (such as paracetamol and ibuprofen) due to increased risk of arrhythmia. During a diarrhoea and vomiting illness, affected individuals should keep well hydrated using oral rehydration therapy (such as Dioralyte). Affected individuals should also be advised to avoid excessive alcohol consumption, cocaine and cannabis use and eating large meals before bed due to increased risk of arrhythmia. […] Implantable cardioverter-defibrillator (ICD) implantation is recommended in individuals who have survived cardiac arrest or have documented episodes of spontaneous ventricular arrhythmia. ICD implantation should be considered in individuals with a spontaneous type 1 Brugada ECG pattern and syncope. Asymptomatic affected individuals may undergo electrophysiology studies to assess whether there is inducible ventricular tachycardia or ventricular fibrillation. Affected individuals with recurrent ventricular arrhythmias may be treated using medication (such as quinidine) or with catheter ablation. Individuals with Brugada syndrome should be considered for genomic counselling (see the National Genomic Test Directory for eligibility criteria).

Zobacz więcej